Nkarta: Finally An Attractive Valuation

luismmolina I have a strong affinity for cell technology tickers attempting to push limits in order to provide cutting-edge therapies to the market to address some of the worst diseases known to man. It wasn't that long ago the FDA approved the first CAR-T therapy, which was Novartis's (NVS) Kymriah (tisagenlecleucel) for acute lymphoblastic leukemia (ALL). Since then there have been a few more CAR-T therapies approved targeting lymphomas and myelomas. However, the development of cell therapies is just gett ...